DeepMed Research

Probenecid

Generic Name: Probenecid

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₉NO_₄S

CAS Number: 57-66-9

Unique Ingredient Identifier: PO572Z7917

Background: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

Indication: For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics.

Associated Conditions: Bacterial Infections, Chronic Gouty Arthritis, Elevated Serum Uric Acid, Gout Chronic, Hyperuricemia, Infection

Clinical Trials

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Warfarin sodium tablets
Drug: Digoxin tablet
Drug: Probenecid tablets
Drug: DBPR108 tablets

First Posted Date: 2021-09-16

Last Posted Date: 2022-03-10

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT05045313

Locations: 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, China

Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal

Phase 2

Recruiting

Conditions: Chronic Pain
Drug Dependence of Morphine Type
Symptom, Withdrawal

Interventions: Drug: Probenecid

First Posted Date: 2021-06-25

Last Posted Date: 2025-03-30

Lead Sponsor: University of Calgary

Target Recruit Count: 40

Registration Number: NCT04939623

Locations: 🇨🇦
Richmond Road Diagnostic and Treatment Centre, Calgary, Alberta, Canada

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

Active, not recruiting

Conditions: Gout

Interventions: Drug: Probenecid
Drug: Allopurinol

First Posted Date: 2021-02-10

Last Posted Date: 2023-07-18

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 294878

Registration Number: NCT04746989

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

The Re-Prosper HF Study

Phase 2

Recruiting

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: probenecid

First Posted Date: 2020-09-16

Last Posted Date: 2025-04-25

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 120

Registration Number: NCT04551222

Locations: 🇺🇸
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
🇺🇸
Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States
🇺🇸
Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States

and more 2 locations

TRPV2 Agonists in the Fontan Circulation

Phase 4

Completed

Conditions: Fontan

Interventions: Drug: Probenecid
Other: Placebo

First Posted Date: 2019-05-29

Last Posted Date: 2021-07-09

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 8

Registration Number: NCT03965351

Locations: 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States

A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04965842
Drug: Probenecid

First Posted Date: 2019-05-03

Last Posted Date: 2019-10-18

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03937258

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: vadadustat
Drug: Cyclosporins
Drug: Probenecid
Drug: Rifampin

First Posted Date: 2019-01-11

Last Posted Date: 2019-03-22

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 40

Registration Number: NCT03801746

Locations: 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Probenecid
Drug: Ciclosporin

First Posted Date: 2018-03-15

Last Posted Date: 2019-06-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT03466567

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Furosemide
Drug: Probenecid
Drug: Metformin
Drug: Rosuvastatin
Drug: Cimetidine
Drug: Verapamil
Drug: Rifampin

First Posted Date: 2017-10-11

Last Posted Date: 2023-11-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT03307252

Locations: 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Bexagliflozin
Drug: Probenecid
Drug: Rifampin
Drug: Verapamil

First Posted Date: 2017-09-28

Last Posted Date: 2021-07-01

Lead Sponsor: Theracos

Target Recruit Count: 48

Registration Number: NCT03296800

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy